Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 6,686 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 6,686 shares of Stoke Therapeutics stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total transaction of $209,539.24. Following the transaction, the insider directly owned 40,798 shares of the company’s stock, valued at approximately $1,278,609.32. This trade represents a 14.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Barry Ticho also recently made the following trade(s):

• On Tuesday, March 17th, Barry Ticho sold 6,164 shares of Stoke Therapeutics stock. The shares were sold at an average price of $33.01, for a total transaction of $203,473.64.
• On Thursday, March 19th, Barry Ticho sold 1,461 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.99, for a total transaction of $43,815.39.

Stoke Therapeutics Stock Up 2.2%

Stoke Therapeutics stock opened at $33.91 on Friday. Stoke Therapeutics, Inc. has a twelve month low of $5.35 and a twelve month high of $40.22. The company has a market capitalization of $2.01 billion, a P/E ratio of 50.61 and a beta of 1.07. The stock’s 50 day moving average is $32.60 and its 200 day moving average is $29.93.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Chardan Capital restated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Wolfe Research assumed coverage on shares of Stoke Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $40.00 price objective on the stock. UBS Group set a $50.00 price objective on shares of Stoke Therapeutics in a research note on Monday, December 15th. HC Wainwright lifted their target price on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Finally, Needham & Company LLC increased their price target on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $39.83.

Institutional Investors Weigh In On Stoke Therapeutics

Several large investors have recently bought and sold shares of the business. Kestra Advisory Services LLC purchased a new position in shares of Stoke Therapeutics during the fourth quarter valued at approximately $26,000. Harbour Investments Inc. grew its position in Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after purchasing an additional 898 shares during the period. Generali Investments Management Co LLC purchased a new stake in Stoke Therapeutics during the 3rd quarter valued at $41,000. BNP Paribas Financial Markets lifted its holdings in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the last quarter.

Key Headlines Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Several firms reaffirmed or raised bullish views and price targets on STOK, supporting buying interest — Chardan reiterated a “Buy” rating. Chardan Capital Reiterates “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)
• Positive Sentiment: BTIG reaffirmed a Buy rating and set a $39 price target, signaling notable upside vs. recent levels and likely attracting momentum buyers. BTIG Research reaffirmation (Benzinga)
• Positive Sentiment: Wedbush raised its price target to $38 and Needham published a bullish outlook for strong price appreciation—additional analyst support that can underpin the rally. Wedbush Boosts Stoke Therapeutics (NASDAQ:STOK) Price Target to $38.00
• Positive Sentiment: Coverage of Stoke’s experimental program highlights broader clinical potential beyond seizure control — reporting suggests the drug aims to reverse developmental loss in Dravet syndrome, which supports longer‑term value. Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces examined a recent sharp pullback and the drivers behind it — useful context for traders but not new company-specific catalyst. Stoke Therapeutics (NASDAQ:STOK) What Triggered This Sudden Drop?
• Negative Sentiment: Multiple insiders (including the CFO, general counsel and other executives) disclosed sizable sales across March 17–19, trimming positions by double-digit percentages — insider selling can weigh on sentiment and prompt investor caution. Representative filing: SEC Form 4 (Jonathan Allan)

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.